{"id":"NCT00419744","sponsor":"AstraZeneca","briefTitle":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","officialTitle":"A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2007-01-09","resultsPosted":"2010-09-16","lastUpdate":"2010-09-16"},"enrollment":1200,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Budesonide/formoterol (SYMBICORT) pMDI","otherNames":[]},{"type":"DRUG","name":"Formoterol Turbuhaler","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.","primaryOutcome":{"measure":"Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year","timeFrame":"12 months","effectByArm":[{"arm":"SYM 160/4.5 X 2 BID","deltaMin":0.75,"sd":null},{"arm":"SYM 80/4.5 X 2 BID","deltaMin":0.84,"sd":null},{"arm":"FOR 4.5 X 2 BID","deltaMin":1.14,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":140,"countries":["United States","Argentina","Brazil","Chile","Colombia","Mexico","Peru","South Africa","Venezuela"]},"refs":{"pmids":["29331313","26293575","25670896","22033040"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":79,"n":407},"commonTop":["Chronic Obstructive Pulmonary Disease","Headache","Nasopharyngitis","Bronchitis","Influenza"]}}